220 related articles for article (PubMed ID: 23734559)
1. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.
Le Naour M; Akgün E; Yekkirala A; Lunzer MM; Powers MD; Kalyuzhny AE; Portoghese PS
J Med Chem; 2013 Jul; 56(13):5505-13. PubMed ID: 23734559
[TBL] [Abstract][Full Text] [Related]
2. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
3. Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
Dvorácskó S; Keresztes A; Mollica A; Stefanucci A; Macedonio G; Pieretti S; Zádor F; Walter FR; Deli MA; Kékesi G; Bánki L; Tuboly G; Horváth G; Tömböly C
Eur J Med Chem; 2019 Sep; 178():571-588. PubMed ID: 31220675
[TBL] [Abstract][Full Text] [Related]
4. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception.
Akgün E; Javed MI; Lunzer MM; Smeester BA; Beitz AJ; Portoghese PS
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11595-9. PubMed ID: 23798416
[TBL] [Abstract][Full Text] [Related]
5. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
[TBL] [Abstract][Full Text] [Related]
7. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
[TBL] [Abstract][Full Text] [Related]
8. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
9. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).
Akgün E; Javed MI; Lunzer MM; Powers MD; Sham YY; Watanabe Y; Portoghese PS
J Med Chem; 2015 Nov; 58(21):8647-57. PubMed ID: 26451468
[TBL] [Abstract][Full Text] [Related]
11. Heteromer Induction: An Approach to Unique Pharmacology?
Portoghese PS; Akgün E; Lunzer MM
ACS Chem Neurosci; 2017 Mar; 8(3):426-428. PubMed ID: 28139906
[TBL] [Abstract][Full Text] [Related]
12. Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia.
Desroches J; Bouchard JF; Gendron L; Beaulieu P
Neuroscience; 2014 Mar; 261():23-42. PubMed ID: 24365460
[TBL] [Abstract][Full Text] [Related]
13. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
15. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.
Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM
Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345
[TBL] [Abstract][Full Text] [Related]
16. An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands.
Yekkirala AS; Kalyuzhny AE; Portoghese PS
ACS Chem Biol; 2013 Jul; 8(7):1412-6. PubMed ID: 23675763
[TBL] [Abstract][Full Text] [Related]
17. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
Zheng Y; Akgün E; Harikumar KG; Hopson J; Powers MD; Lunzer MM; Miller LJ; Portoghese PS
J Med Chem; 2009 Jan; 52(2):247-58. PubMed ID: 19113864
[TBL] [Abstract][Full Text] [Related]
18. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
19. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
[TBL] [Abstract][Full Text] [Related]
20. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR-DOR Heteromer.
Akgün E; Lunzer MM; Tian D; Ansonoff M; Pintar J; Bruce D; Hawkinson JE; Wilcox GL; Portoghese PS
Biochemistry; 2021 May; 60(18):1413-1419. PubMed ID: 32930576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
